Notably, emerging therapeutic agents such as glucagon-like peptide-1 (GLP-1) receptor agonists have shown promise in addressing multiple aspects of MetS, including glycemic control, weight reduction, and cardiovascular risk reduction [10]. This evidence concerns the gene GLP1R and metabolic syndrome.